Earnings miss the fly in the ointment for Pfizer

2 February 2021

Shares in US pharma giant Pfizer (NYSE: PFE) dropped by more than 2% on Tuesday morning despite the group’s quarterly and annual results reflecting a company with much to be positive about.

The market reaction was probably due to Pfizer’s quarterly adjusted diluted earnings per share (EPS) missing the $0.48 anticipated by analysts, at $0.42, even though this figure was still a 14% increase on the same period in 2019.

"Right away, our ability to move quickly and utilize cutting-edge science to help address the world’s most important medical challenges was put to the test by the COVID-19 pandemic"Revenue rose 12% year-on-year to $11.7 billion, above the consensus forecast of $11.4bn, with the full-year 2020 sales figure coming in at $41.91 billion, a 2% increase. Adjusted diluted EPS for the year was up 16% at $2.22.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK